Malaria-associated bacteremia accounts for up to one-third of deaths from severe malaria, and non-typhoidal Salmonella (NTS) has been reported as a major complication of severe malarial infection.
Plasmodium falciparum, the most deadly agent of malaria, displays a wide variety of resistance mechanisms in the field.
Available anti-malarial tools have over the ten-year period, 2002 to 2012, dramatically reduced the number of fatalities attributed to malaria, from one million to less than six-hundred and thirty thousand.
Chemical investigation of the organic extract obtained from the sponge Plakortis simplex collected in the South China Sea afforded five new polyketide endoperoxides (2 and 4–7), along with two known analogues (1 and 3).
The usefulness of atovaquone-proguanil (AP) as an antimalarial treatment is compromised by the emergence of atovaquone resistance during therapy.
No abstract available
Ex vivo antimalarial sensitivity testing in human malaria parasites has largely depended on microscopic determination of schizont maturation.
An efficient one pot synthesis of a series of pluripotent (E)-1-(3-methyl-5-aryl-7-styryl-5H-thiazolo[3,2-a]pyrimidin-6-yl)-3-arylprop-2-en-1-ones is reported.
This study assessed the health systems capacity to absorb PMD at primary health care facilities in Uganda.
These compounds (1–4) exhibited potent anti-Plasmodium palcifarum K1 strain with IC50 values in a range of 0.0534–2.93 μg/mL and anti-Mycobacterium tuberculosis with minimum inhibition concentrations (MICs) in a range of 3.13–12.50 μg/mL. Cytotoxicity against KB, MCF-7, NCI-H187, and Vero cells was also evaluated.